Biocept (BIOC) Q4 EPS Beats Consensus, Revenues Beat (Correction)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
March 29, 2021 4:05 PM EDTQ4 features revenues of $18.5 million; 2020 revenues reach $27.5 million driven by COVID-19 testing
Introduces strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system
Conference call begins at 4:30 p.m. Eastern time today
SAN DIEGO--(BUSINESS... More
